Biogen Inc. (NASDAQ:BIIB), a leading biopharmaceutical company specializing in neurology and rare diseases, finds itself at a critical juncture as it navigates a complex landscape of opportunities and ...

After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on ...

With the prospects for its Alzheimer’s drug aducanumab still up in the air, Biogen has moved to shore up its late-stage pipeline with a $3 billion licensing deal with Sage that adds drugs for ...

The company's future hinges on the success of key products like Leqembi for Alzheimer's disease and Skyclarys for Friedreich's ataxia, while grappling with an underdeveloped pipeline and a declining ...

In addition, Sage and Biogen discontinued SAGE-324 in essential tremor in July after a midstage trial flop. Now, Sage's pipeline consists of several programs in GABA hypofuction and a candidate in ...

Biogen has moved to acquire rights for a late ... a string of mid-sized molecule acquisitions to help bolster its pipeline. One made already is the $300 million upfront payment for BMS’ BMS ...

alongside an underdeveloped pipeline and insufficient rare disease portfolio, underpins Seigerman’s decision to maintain a Hold rating for Biogen. In another report released on January 13 ...

Biogen's pipeline has faced recent setbacks, including the discontinuation of SAGE-324 (BIIB124) for essential tremor following disappointing Phase 2 results. This adds to a series of recent ...